Navigation Links
Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
Date:10/1/2007

Study Data Show Patients with Moderate to Severe Psoriasis Who Responded to Anti-IL-12/23 ABT-874 after 12 Weeks of Treatment, Maintained Response at

24 Weeks

BUENOS AIRES, Argentina, Oct. 1 /PRNewswire-FirstCall/ -- Results from an extension to a Phase II study evaluating the effectiveness of Abbott's (NYSE: ABT) investigational anti-IL-12/23 antibody ABT-874 showed that a majority of patients who initially responded to treatment maintained a high level of response following discontinuation of therapy. In the study, patients who achieved 75 percent improvement in psoriasis signs and symptoms (PASI 75) at 12 weeks stopped receiving ABT-874. At 24 weeks, more than two- thirds of these patients maintained at least 50 percent improvement (PASI 50). The Phase II study, conducted in patients with moderate to severe psoriasis, will be presented at the World Congress of Dermatology in Buenos Aires.

Phase II results presented earlier this year at the Society for Investigative Dermatology (SID) Meeting showed ABT-874 reduced psoriasis symptoms significantly in the majority of patients treated. At 12 weeks, at least 90 percent of patients with moderate to severe psoriasis achieved 75 percent improvement in psoriasis signs and symptoms in all but the lowest dosing groups receiving ABT-874, versus 3 percent of patients receiving placebo. Also, more than half of patients achieved 90 percent improvement, in the same four of five ABT-874 dosing groups, versus 0 percent of those receiving placebo.

"ABT-874 represents a novel approach to treating psoriasis, targeting a part of the inflammatory response that is not addressed by any therapy available today," said Alan Menter, MD, Chair,
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
(Date:9/30/2014)... LEXINGTON, Ky. , Sept. 30, 2014 ... coherence tomography (OCT), offered a new look at the ... to alter how physicians understand and treat the disease, ... study, conducted at Baptist Health Lexington between September 2010 ... issue of the Journal of the American College ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... , , VENLO, Netherlands , Feb. 2 QIAGEN N.V. ... financial results call. The Webcast will take place at 9:30 a.m. EST on ... President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer. , ... QIAGEN,s fourth quarter and year-end 2009 financial , ...
... , JERUSALEM , Feb. ... ) announced today the availability of new resources to support ... to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] brand ... due to inadequate secretion of normal endogenous growth hormone. The ...
Cached Medicine Technology:Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 2Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 2Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 4Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 5Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 6
(Date:10/1/2014)... This October, Request A Test , a leading ... 10% off all testing for Diabetes . Customers ... save. The Center for Disease Control (CDC) reports that ... Diabetes. Because many people do not display symptoms, it ... serious health problems. Blood testing can help a person ...
(Date:10/1/2014)... October 01, 2014 After a run ... "Beautiful Births", emerging filmmaker Jacqui Blue is continuing her ... discover the truth about natural birth. The documentary has ... over the world and has been an effective medium ... the topics highlighted in the film provide a wealth ...
(Date:10/1/2014)... 01, 2014 The Oliver Law ... new Other-Sonic Ultrasound Gel lawsuit web page ... the litigation surrounding the 2011 Pseudomonas aeruginosa / ... Royal Oak, Michigan, which was ultimately traced to ... representing William Beaumont patients who allegedly became ill ...
(Date:10/1/2014)... October 01, 2014 Indosoft, Inc., a leading ... announces that it has added support for Sangoma Lyra ... and Indosoft have a history of bringing innovative ... patent-pending technology offers a significant benefit to those using Asterisk ... is now available to users of Q-Suite. , In the ...
(Date:10/1/2014)... 01, 2014 The annual Social Security cost-of-living ... 2015, says a new forecast by The Senior Citizens ... price index (CPI) data through August, TSCL forecasts that COLAs ... the sixth consecutive year of record low COLAs,” states TSCL ... became automatic in 1975,” he notes. , Over the past ...
Breaking Medicine News(10 mins):Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 2Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 4Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 2Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 4Health News:Indosoft Announces Q-Suite Support For Sangoma Lyra 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3
... , TUESDAY, Jan. 24 (HealthDay News) -- People without ... medical care or prescription drugs than people with jobs who ... the depths of the recent recession, unemployment reached 9.6 percent, ... access to care and most people rely on getting insured ...
... , TUESDAY, Jan. 24 (HealthDay News) -- Children with ... gastroesophageal reflux don,t get additional asthma control from acid-reducing ... these medications when there are no digestive issues increases ... the study. "There,s a strong epidemiological link between ...
... , TUESDAY, Jan. 24 (HealthDay News) -- If you have ... of painful flare-ups, new research suggests. The new study ... in the previous four months. They were divided into three ... or skim milk powder enriched with glycomacropeptide (GMP) and G600 ...
... from Rhode Island Hospital reports on the impact to ... upcoming revision to the Diagnostic and Statistical Manual, 5th ... these changes could result in false-negative diagnoses for patients. ... Clinical Psychiatry and is now available online in ...
... announce that it has entered a new long-term collaboration with ... journal Alcohol and Alcoholism . At the end ... the journal Alcohol and Alcoholism , which was previously ... founded in 1967 to improve the understanding and management of ...
... German . Studies currently available provide ... be detected and treated earlier, and consequently tumours occur less ... In this context, an HPV test can be used alone ... both screening procedures also carry a risk of harm in ...
Cached Medicine News:Health News:Even With Insurance, Unemployed Have Worse Health Outcomes 2Health News:Even With Insurance, Unemployed Have Worse Health Outcomes 3Health News:Heartburn Meds Won't Help, May Harm Kids With Asthma 2Health News:Heartburn Meds Won't Help, May Harm Kids With Asthma 3Health News:Enriched Skim Milk Good for Gout, Study Suggests 2Health News:The impact of deleting 5 personality disorders in the new DSM-5 2Health News:Oxford University Press and Medical Council on Alcohol announce long-term partnership 2Health News:HPV testing: Indications of a benefit in primary screening 2Health News:HPV testing: Indications of a benefit in primary screening 3Health News:HPV testing: Indications of a benefit in primary screening 4
... The National Laboratory Training Network (NLTN) ... Association of Public Health Laboratories (APHL) and ... (CDC). NLTN provides cost-effective training in a ... resources, including a FREE Lending Library. Log ...
... The AAFP-PT Laboratory Proficiency Testing and ... programs are designed to assist POLs, clinics ... are designed to assure accuracy of patient ... regulatory requirements. Participation provides the opportunity to ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) of IgM isotype in human serum....
Medicine Products: